Anavex生命科学公司2025年第一季度GAAP每股收益$(0.14)好于预期$(0.19),截至2024年12月31日公司现金及现金等价物为1.208亿美元,按当前现金使用率和范围预计可维持约4年

财报速递
12 Feb
Anavex生命科学公司(NASDAQ:AVXL)报告季度亏损为每股$(0.14),好于分析师预期的每股$(0.19),超出26.32%。这一结果较去年同期每股亏损$(0.11)下降了27.27%。

以上内容来自Benzinga Earnings专栏,原文如下:

Anavex Life Sciences (NASDAQ:AVXL) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.19) by 26.32 percent. This is a 27.27 percent decrease over losses of $(0.11) per share from the same period last year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10